Dr. Javier San Martin Net Worth

The estimated Net Worth of Martin Javier San is at least $8.98 Million dollars as of 4 January 2024. Dr San owns over 8,303 units of Arrowhead Pharmaceuticals stock worth over $4,156,527 and over the last 4 years he sold ARWR stock worth over $4,149,579. In addition, he makes $673,571 as Chief Medical Officer at Arrowhead Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dr Martin ARWR stock SEC Form 4 insiders trading

Dr has made over 5 trades of the Arrowhead Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 8,303 units of ARWR stock worth $292,764 on 4 January 2024.

The largest trade he's ever made was selling 19,700 units of Arrowhead Pharmaceuticals stock on 20 November 2023 worth over $567,360. On average, Dr trades about 12,358 units every 163 days since 2020. As of 4 January 2024 he still owns at least 198,497 units of Arrowhead Pharmaceuticals stock.

You can see the complete history of Dr San stock trades at the bottom of the page.

Dr. Javier San Martin biography

Dr. Javier San Martin is the Chief Medical Officer at Arrowhead Pharmaceuticals.

What is the salary of Dr Martin?

As the Chief Medical Officer of Arrowhead Pharmaceuticals, the total compensation of Dr Martin at Arrowhead Pharmaceuticals is $673,571. There are 5 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of $2,216,260.

How old is Dr Martin?

Dr Martin is 55, he's been the Chief Medical Officer of Arrowhead Pharmaceuticals since . There are 9 older and 7 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.

What's Dr Martin's mailing address?

Martin's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.

Insiders trading at Arrowhead Pharmaceuticals

Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone, and Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.

What does Arrowhead Pharmaceuticals do?

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing

Complete history of Dr San stock trades at Arrowhead Pharmaceuticals and Athira Pharma

Arrowhead Pharmaceuticals executives and stock owners

Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include:

• Christopher Anzalone,
  President, Chief Executive Officer, Director
• Kenneth Myszkowski,
  Chief Financial Officer
• Dr. Christopher R. Anzalone,
  CEO, Pres & Director
• Patrick O'Brien,
  General Counsel
• Kenneth A. Myszkowski,
  Chief Financial Officer
• Dr. Javier San Martin M.D.,
  Chief Medical Officer
• Dr. Javier San Martin,
  Chief Medical Officer
• Douglass Given,
  Chairman of the Board
• Michael Perry,
  Lead Independent Director
• James Hassard,
  Chief Commercial Officer
• Dr. Bruce D. Given,
  Advisor
• William Waddill,
  Independent Director
• Mauro Ferrari,
  Independent Director
• Vincent Anzalone,
  IR Contact Officer
• Oye Olukotun,
  Independent Director
• Marianne De Backer,
  Independent Director
• Javier San Martin,
  Chief Medical Officer
• James Hassard,
  Chief Commercial Officer
• Curt Bradshaw,
  Chief Scientific Officer
• Dr. Mark Seefeld,
  Head of Toxicology & VP
• Dr. James C. Hamilton,
  Sr. VP of Discovery & Translational Medicine
• Patrick O'Brien,
  Chief Compliance Officer, Gen. Counsel & Corp. Sec.
• Howard Lovy,
  Director of Communications
• Jane Davidson,
  Head of HR & Admin., VP and Corp. Sec.
• Dr. Mark M. Davis,
  Founder and Founder & Director of Insert Therapeutics Inc & Calando
• Bruce D Given,
  Chief Operating Officer
• Edward W Frykman,
  Director
• David M Knott,
  10% owner
• Douglas B Given,
  Director
• David L. Lewis,
  Chief Scientific Officer
• Joseph Theodore Iii Kingsley,
  Chief Financial Officer
• Zhen Li,
  Snr. VP, Chem and Non-Clin Dev
• Peter Brian Leone,
  VP, Strategy & Program Mgmt
• Victoria Vakiener,
  Director
• Leon Ekchian,
  President
• Marshall Robert Ching,
  10% owner
• James M Jr Phillips,
  Secretary
• Charles Mc Kenney,
  Director
• R Bruce Stewart,
  President
• Leroy T Rahn,
  Director
• Paul Clayton Mc Donnel,
  Chief Financial Officer
• James C Hamilton,
  Chief Discovery/Trans Medicine
• Hongbo Lu,
  Director
• Tracie Oliver,
  Chief Commercial Officer